Earnings ·
Reports Q3 net sales of $35.5 million, up 30%, and updates full-year revenue guidance to $124M-$126M
BBNXBeta Bionics, Inc.
Beta Bionics reported third-quarter net sales of $35.5 million, a 30% increase from the prior year period, driven by strong growth in its Pharmacy Benefit Plan channel which saw sales rise 118% to $13.6 million. The company raised its full-year 2026 revenue guidance to an estimated $124 million to $126 million, up from the previous range of $121 million to $126 million, citing potential deferral impacts as new users await the Mint launch. Beta Bionics operates in the medical device industry, designing and commercializing advanced diabetes management solutions including adaptive closed-loop insulin delivery systems.